IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:)	
O'Brien et al.)	
Serial No.: 09/965,738)	
Filed: September 27, 2001)	
For: REPEAT SEQUENCES OF THE CA125 GENE AND THEIR USE FOR DIAGNOSTIC AND THERAPEUTIC INTERVENTIONS)))	Attorney Docket No.: 022438.43865 (Formerly 40715-260477)

STATEMENT UNDER 37 C.F.R. 1.821(f)

Karen A. Lacourciere Primary Examiner Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

4-16-04

Sir:

I hereby state that the information recorded in computer readable form is identical to the written substitute sequence listing and contains no new matter.

Respectfully Submitted,

BUTLER, SNOW, O'MARA, STEVENS & CANNADA, PLLC

Susan B. Fentress

Reg. No. 31,327

P.O. Box 171443 Memphis, TN 38187 (901) 680-7319

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as U.S. First Class Mail, postage prepaid, on ________ in an envelope addressed to: Karen A. Lacourciere, Primary Examiner, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

U.S. Application No.: 09/965,738

p. 21; l. 1

confirmed the stop-codon indicated (TGA) as well as the poly A signal sequence (AATAA) (SEQ ID NO: 310) and

AMENDMENT TO THE SEQ ID LISTING

Please delete pages 1-381 and add pages 1-299.

Respectfully Submitted,

Butler, Snow, O'Mara, Stevens & Cannada, PLLC

4-16-04

By: _

SUSAN B. FENTRESS

Reg. No. 31,327

6075 Poplar Avenue, Suite 500

Memphis, TN 38119 (901) 680-7319

CERTIFICATE OF MAILING

LORI L. WOOD

\o'	1. E. S.	Application No. (00/065 729
APR 2	2 0 2004	. Application No.: <u>09/965,738</u>
ENT & TR	NOTIGE NUCEE ADEMAN	TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING OTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES
	Applican the Notic	It must file the items indicated below within the time period set the Office action to which ce is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be under the provisions of 37 CFR 1.136(a)).
	comply v	leotide and/or amino acid sequence disclosure contained in this application does not with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the reason(s):
		1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
		2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
		3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
		4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
		5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
		The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
	×	7. Other: This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. 1.821 (a)(1) and (a)(2), however, this application fails to comply with the sequence rules. For example, see page 19, lines 18 and 27.
	Ap	plicant Must Provide:
•	X	An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
•	* X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
	X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
	Foi	r questions regarding compliance to these requirements, please contact:
	For For	r Rules Interpretation, call (703) 308-4216 - 571-872-095 / r CRF Submission Help, call (703) 308-4212
	Pat	tentIn Software Program Support
		Technical Assistance

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY

To Purchase Patentin Software.....703-306-2600